Semaglutide Guide: Weight Loss, Side Effects & Tips for Safe Use

Weight management is influenced by far more than diet and exercise alone. Research shows that hormones, metabolism, appetite regulation, genetics, and lifestyle factors all play an important role in obesity and long-term weight gain. [1] For many individuals in India, persistent hunger cravings and difficulty maintaining weight loss make traditional approaches challenging, increasing interest in medically guided weight management solutions.

One medication that has gained significant attention globally and in India is semaglutide, the active ingredient in Wegovy and Ozempic. Originally developed for type 2 diabetes management, semaglutide is now widely used for chronic weight management because of its ability to regulate appetite, increase satiety, and support reduced calorie intake. As a GLP-1 receptor agonist, it mimics a natural hormone involved in hunger signalling, digestion, and blood sugar control. [2] [3]

With the growing popularity of semaglutide for weight loss in India, and the availability of generic semaglutide following patent expiry in 2026, many people want to understand how it works, the potential side effects, expected weight loss results, and whether treatments like Wegovy or Ozempic are suitable for long-term use. [21] Understanding these factors is essential before starting any prescription-based weight management treatment.

In this guide, we explore the science behind semaglutide, including how it supports weight loss, differences between Wegovy and Ozempic, common side effects, and practical tips for safe use. At Karespot, semaglutide-based weight management plans are guided by qualified Internal Medicine specialists and Endocrinologists who provide personalised medical supervision, ongoing monitoring, and lifestyle support.

Semaglutide is a prescription GLP-1 receptor agonist medication originally developed to help manage blood sugar levels in people with type 2 diabetes. Today, it is also widely recognised for its role in chronic weight management. It is the active ingredient found in Wegovy and Ozempic, both administered as once-weekly injections under medical supervision. [3]

Semaglutide works by mimicking GLP-1, a natural hormone involved in appetite regulation, digestion, insulin release, and feelings of fullness. By activating GLP-1 receptors, the medication helps reduce hunger cravings, slow gastric emptying, and increase satiety, which may help individuals consume fewer calories and better manage their weight over time. [3, 5]

Semaglutide supports weight loss by targeting key biological pathways involved in appetite regulation, digestion, and metabolic control. Unlike traditional weight loss methods that focus only on calorie reduction, semaglutide works at a hormonal level to influence hunger, fullness, and eating behaviour. [5] This is one reason why Wegovy and Ozempic have become important tools in medically supervised weight management across India and globally.

As a GLP-1 receptor agonist, semaglutide mimics glucagon-like peptide-1, a natural hormone released after eating. By activating GLP-1 receptors in the brain and digestive system, it helps reduce food cravings, increase feelings of fullness, and improve appetite control. It also slows gastric emptying, helping individuals stay satisfied for longer periods after meals. [5]

Long-term weight loss can be difficult because the body often responds to calorie restriction by increasing hunger signals and reducing metabolic efficiency. Semaglutide helps counter some of these biological responses, making it easier for some individuals to reduce portion sizes, avoid frequent snacking, and maintain healthier eating habits without constant hunger. [6]

Clinical studies, including the large-scale STEP trials and the SELECT cardiovascular outcomes trial, confirm that semaglutide may support significant and sustained weight reduction when combined with balanced nutrition, regular physical activity, and long-term lifestyle support. The SELECT trial also demonstrated a 20% reduction in major adverse cardiovascular events in people with overweight or obesity. [10] [20] [20] Individual results can vary depending on metabolic health, treatment adherence, and overall lifestyle habits.

Semaglutide acts on appetite-regulating centres in the hypothalamus, helping reduce hunger and improve portion control. Many individuals using Wegovy or Ozempic report fewer cravings, reduced emotional eating, and better control over daily calorie intake. Research from the STEP 5 trial confirms meaningful reductions in eating behaviours including emotional and uncontrolled eating. [5] [8] [5]

Semaglutide also supports metabolic health by improving insulin response and helping stabilise blood sugar levels. This is particularly relevant for Indian patients, who are at higher risk for insulin resistance and type 2 diabetes due to the "thin-fat" or metabolically obese normal weight (MONW) phenotype common in South Asians, where individuals may carry significant metabolic risk at lower BMI values than Western populations. [21]

Semaglutide may be prescribed for adults with obesity or excess weight, especially when diet and exercise alone have not produced sustainable results. In the Indian context, eligibility criteria may also consider lower BMI thresholds, given that metabolic risks in South Asian populations occur at lower BMI values compared with Western populations. [21]

In general, semaglutide may be recommended for individuals with a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with weight-related conditions such as type 2 diabetes, high blood pressure, insulin resistance, sleep apnoea, or high cholesterol. [23] It may also benefit individuals struggling with persistent hunger, emotional eating, or difficulty controlling portion sizes.

Because semaglutide affects appetite, metabolism, and blood sugar regulation, treatment suitability should always be assessed by qualified healthcare professionals. The medication carries an FDA boxed warning regarding thyroid C-cell tumours observed in rodent studies and is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). [23] Pregnant or breastfeeding individuals are generally advised to avoid semaglutide unless medically recommended.

Weight loss results with semaglutide can vary based on factors such as body weight, metabolic health, dosage progression, nutrition, physical activity, and long-term treatment adherence. The STEP trial programme provides robust evidence for semaglutide's efficacy. [22]

In the STEP 1 trial, adults using once-weekly semaglutide 2.4 mg alongside diet and exercise lost a mean of 14.9% of their initial body weight over 68 weeks versus 2.4% with placebo. [22] The two-year STEP 5 trial confirmed sustained weight loss of approximately 15.2% at 104 weeks. [9] A Phase III trial conducted specifically in Indian adults with obesity reported non-inferior weight loss of 11.25% at 24 weeks. [21] The 2025 STEP UP trial found that an investigational 7.2 mg dose achieved 18.7% weight loss over 72 weeks in the primary analysis (treatment policy estimand), and 20.7% among patients who adhered to treatment (trial product estimand). Next-generation multi-receptor agonists such as retatrutide and the CagriSema combination are showing even greater potential in early trials. 12 [7]

Semaglutide injections are usually started at a low dose and gradually increased over several weeks to help the body adjust and reduce gastrointestinal side effects such as nausea, bloating, and stomach discomfort. This gradual dose escalation, also known as titration, is an important part of safe treatment. [11]

Semaglutide is typically administered as a once-weekly injection under the skin of the abdomen, thigh, or upper arm. [11] Gradual dose escalation allows the digestive system and appetite-regulating pathways to adapt more comfortably to GLP-1 receptor activation. Higher doses do not always result in faster weight loss. The most effective semaglutide dosage is one that balances treatment benefits, tolerability, and long-term sustainability under proper medical supervision.

Semaglutide should not be stopped abruptly without medical guidance. Because Wegovy and Ozempic affect appetite regulation, digestion, and metabolism, discontinuing treatment may lead to increased hunger, changes in eating patterns, and possible weight regain over time. Evidence from the STEP 1 extension study shows that mean body weight returned toward baseline within one year of stopping semaglutide. [18]

Some individuals may stop semaglutide after reaching their weight management goals, while others may discontinue treatment due to side effects, pregnancy planning, medication costs, or changes in health status. [18] Healthcare providers may sometimes recommend gradual dosage adjustments or alternative treatment strategies depending on the individual's response and long-term goals.

Like all prescription medications, semaglutide may cause side effects in some individuals, although not everyone experiences them to the same degree. Wegovy and Ozempic influence appetite regulation, digestion, and blood sugar control, which means many of the most common side effects are related to the gastrointestinal system. In most cases, these symptoms are mild to moderate and tend to improve gradually as the body adjusts to treatment. [13]

The most frequently reported side effects include nausea, vomiting, diarrhoea, constipation, bloating, stomach discomfort, and reduced appetite. [13] Nausea is particularly common during the early stages of treatment or after dose increases because semaglutide slows gastric emptying and affects satiety signalling. Eating smaller meals, staying hydrated, avoiding heavy fatty foods, and following the prescribed dose escalation schedule may help reduce these symptoms.

Semaglutide carries an FDA boxed warning regarding the potential risk of thyroid C-cell tumours based on animal studies. It is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). [23] More serious risks requiring prompt medical attention include severe abdominal pain, pancreatitis, gallbladder disease, persistent vomiting, severe dehydration, allergic reactions, or worsening kidney function. [13] [17] [13]

Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist that helps regulate appetite and blood sugar levels. Although they share the same active ingredient, they are approved for different primary uses and prescribed at different dosage strengths. [14] [15]

Ozempic is mainly approved for type 2 diabetes management and may also support weight loss as a secondary benefit. [3] Wegovy is specifically approved for chronic weight management in adults with obesity or overweight conditions linked to metabolic health risks. One major difference is dosage: Wegovy is prescribed at a higher maintenance dose of 2.4 mg weekly, which may contribute to greater average weight loss. [14, 15]

Wegovy is generally considered the semaglutide formulation specifically designed for chronic weight management because it is prescribed at a higher maintenance dose. However, the best option depends on factors such as metabolic health, diabetes status, medical history, weight management goals, and individual treatment response. [15]

While there is no strict semaglutide diet, certain foods may worsen gastrointestinal side effects or interfere with overall weight management progress during treatment. Because Wegovy and Ozempic slow gastric emptying and influence appetite regulation, some individuals may become more sensitive to heavy meals, greasy foods, and highly processed products. [16, 16]

One of the most commonly reported side effects is nausea, especially during the early stages of treatment or after dose increases. [13] Foods that are high in fat, fried, heavily processed, or excessively sugary may aggravate nausea, bloating, acid reflux, or stomach discomfort. [16, 16] For Indian patients, this may include limiting very oily curries, deep-fried snacks such as samosas, pakoras, and puri, high-sugar sweets like mithai and sugary lassi, and high-glycaemic-index foods like white rice in large portions.

Alcohol intake may also require caution during semaglutide treatment. [13] Excessive alcohol consumption can worsen dehydration, gastrointestinal irritation, blood sugar fluctuations, and nausea. In addition, heavy alcohol intake may increase the risk of pancreatitis, which is a rare but potentially serious condition associated with GLP-1 receptor agonist therapies.

For many individuals with obesity or metabolic health conditions, semaglutide may offer significant benefits when used under proper medical supervision. The SELECT trial demonstrated not only weight loss but a 20% reduction in major adverse cardiovascular events in people with overweight or obesity, even without diabetes. [19] [20] The FLOW trial further demonstrated a 24% reduction in kidney disease progression in adults with type 2 diabetes and chronic kidney disease.

Healthcare providers often weigh the risks of semaglutide against the long-term health risks associated with untreated obesity, including type 2 diabetes, cardiovascular disease, hypertension, sleep apnoea, and fatty liver disease, all highly prevalent in India. [1, 21] For many eligible individuals, the potential health benefits of sustained weight loss may outweigh the manageable risks of treatment when properly monitored.

Starting semaglutide is only the beginning. Research consistently shows that GLP-1 therapy produces the best long-term outcomes when medication is embedded within a structured, multi-disciplinary support programme, not prescribed in isolation. [1] At Karespot, the Kare Programme is built around exactly this principle: a team of GLP-1 specialists working together around each patient, so that side effects are managed, nutrition is optimised, and the psychological dimensions of weight loss are fully supported.

The three pillars of the Kare Programme, a GLP-1 specialist doctor, expert dietitian, and clinical psychologist, work as an integrated unit. Each specialist communicates with the others, ensuring that what happens in one consultation informs the others. This is how Karespot moves beyond a simple prescription service into a genuine, whole-person care model.

Each pillar of the Kare Programme reinforces the others. When nausea is severe, the Kare Nutritionist adjusts meal composition while the Kare Physician reviews whether a dose pause is appropriate. When emotional eating re-emerges under stress, the Kare Mind specialist and Kare Nutritionist coordinate strategies. When weight loss plateaus, the physician reviews metabolic markers, the nutritionist recalibrates energy targets, and the psychologist addresses any motivational or behavioural barriers.

This is the standard of care that specialist obesity clinics in the UK and US have offered in person for years. Karespot brings it to Indian patients entirely online, with no travel, no waiting rooms, and no repeat in-person visits, through a seamless telehealth platform that puts your whole care team within reach whenever you need them.